BioRegenx, Inc. was created to establish a new approach to wellness through a comprehensive line of targeted health diagnostic tools, dietary supplements, and life enhancement products, combined with an effective direct-to-practitioner and consumer sales model. Through its subsidiaries, BioRegenx is poised to capture a significant portion of the approximately $5 trillion health and wellness market1.
BioRegenx possesses vision, insight, and experience coupled with patented technology and products. These assets will allow BioRegenx to embrace the future of microvascular health and well-being for a better present and future. The proven direct-to-practitioner and consumer model encourages participation in sales revenue from independent brand partners that assures deep penetration into the health and wellness market.
The current asset portfolio includes first-to-market, clinically relevant, patented technology for monitoring the microvascular system and a proprietary line of dietary supplements designed to support microvascular health and wellness. These assets are supported by leading-edge products and services such as epigenetics.
Who We Are
BioRegenx is positioning itself as a forerunner in the high-growth sector of regenerative healthcare solutions through the acquisition of Microvascular Health Solutions, LLC, MyBodyRx, LLC, NuLife Sciences, Inc., and TruEpigenetics.
Microvascular Health Solutions brings Endocalyx Pro, a patented and clinically tested dietary supplement that improves the function of the endothelial glycocalyx — an elemental part of the microvascular system. Within the Microvascular Health Solutions eco system is the GlycoCheck System, which allows for the measurement and evaluation of the microvascular system and prolonged benefits of Endocalyx Pro.
The wide-ranging dietary supplement portfolio of MyBodyRX ensures that consumers of these products can not only extend the health of their microvascular system but have the most common supplemental needs in the target demographic addressed. These include vitamins, amino acids, minerals, antioxidants, and more. Bringing to bare the TruEpigentics platform for DNA health will further identify specific supplementation products to improve health long term.
The effective penetration of these products and systems into the market hinges on the direct-to-practitioner and customer model via an independent brand partners distribution platform developed by NuLife Sciences.
BioRegenx is the exclusive distributor through Microvascular Health Solutions of the Glycocheck System. This first-of-its-kind patented technology can monitor and measure the microvascular system. The clinically relevant data and analysis can be used as a tool by practitioners to guide patients to better microvascular system health profiles using the patented Endocalyx Pro and other MyBodyRx products.
The patented Endocaylyx Pro is a unique dietary supplement that is clinically shown to restore, regenerate, and protect the microvascular system — specifically the endothelial glycocalyx.
BioRegenx, by way of its subsidiaries and strategic partners, has established a strong patent and trademark strategy to protect its intellectual property (IP) portfolio from infringement. Currently, BioRegenx holds 12 patents in the US and major international territories including Canada, Europe, China, Japan, and South Korea.
Advanced medical technology devices are one of the fastest growing sectors in the technology market space. Within this category, there is a growing demand for better and more affordable technology along with monitoring platforms for a wide array of health and metabolic health degradation conditions. The GlycoCheck System fits remarkably well within this market sector.